Galafold Oral Chaperone Therapy Reimbursed in Canada

Galafold Oral Chaperone Therapy Reimbursed in Canada

The Canadian Drug Expert Committee (CDEC) and INESSS (Quebec) have recommended in favour of reimbursement of Galafold for long-term treatment of adults with a confirmed diagnosis of Fabry Disease and who have an amenable mutation.  Funding is now available in all provinces & territories throughout Canada for amenable patients through exceptional access and/or special drug programs that meet the guidelines of Canadian Fabry Disease Treatment eligibility.  For more information please follow-up with your Fabry physician.

For more information on Galafold or Amicus Therapeutics, Inc please visit https://www.amicusrx.com/